These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 28968412)

  • 1. Comparison of intraocular pressure-lowering effects of ripasudil hydrochloride hydrate for inflammatory and corticosteroid-induced ocular hypertension.
    Yasuda M; Takayama K; Kanda T; Taguchi M; Someya H; Takeuchi M
    PLoS One; 2017; 12(10):e0185305. PubMed ID: 28968412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Suganami H; Araie M;
    Acta Ophthalmol; 2015 Jun; 93(4):e254-60. PubMed ID: 25487877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Fukushima A; Suganami H; Araie M;
    Acta Ophthalmol; 2016 Feb; 94(1):e26-34. PubMed ID: 26338317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of adding ripasudil to existing treatment regimens for reducing intraocular pressure.
    Inoue K; Okayama R; Shiokawa M; Ishida K; Tomita G
    Int Ophthalmol; 2018 Feb; 38(1):93-98. PubMed ID: 28063100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of raised intraocular pressure in uveitic eyes with and without a corticosteroid-induced hypertensive response.
    Sallam A; Sheth HG; Habot-Wilner Z; Lightman S
    Am J Ophthalmol; 2009 Aug; 148(2):207-213.e1. PubMed ID: 19403113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Ocular Hypertension in Adults with Noninfectious Uveitis.
    Daniel E; Pistilli M; Kothari S; Khachatryan N; Kaçmaz RO; Gangaputra SS; Sen HN; Suhler EB; Thorne JE; Foster CS; Jabs DA; Nussenblatt RB; Rosenbaum JT; Levy-Clarke GA; Bhatt NP; Kempen JH;
    Ophthalmology; 2017 Aug; 124(8):1196-1208. PubMed ID: 28433444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Efficacy and Safety of Latanoprost/Timolol versus Travoprost/Timolol Fixed Combinations for Ocular Hypertension Associated with Uveitis.
    Takeuchi M; Kanda T; Taguchi M; Shibata M; Mine I; Sakurai Y
    Ocul Immunol Inflamm; 2017 Feb; 25(1):105-110. PubMed ID: 26799307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraocular pressure-lowering effects of Ripasudil: a potential outcome marker for Trabeculotomy.
    Goda E; Hirooka K; Mori K; Kiuchi Y
    BMC Ophthalmol; 2019 Dec; 19(1):243. PubMed ID: 31791272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma.
    Kusuhara S; Katsuyama A; Matsumiya W; Nakamura M
    Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):809-814. PubMed ID: 29468405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Ripasudil in Japanese Patients with Glaucoma or Ocular Hypertension: 3-month Interim Analysis of ROCK-J, a Post-Marketing Surveillance Study.
    Tanihara H; Kakuda T; Sano T; Kanno T; Imada R; Shingaki W; Gunji R
    Adv Ther; 2019 Feb; 36(2):333-343. PubMed ID: 30610614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Rho-Associated Kinase Inhibitor Protects Permeability in a Cell Culture Model of Ocular Disease, and Reduces Aqueous Flare in Anterior Uveitis.
    Yamada H; Yoneda M; Inaguma S; Gosho M; Murasawa Y; Isogai Z; Zako M
    J Ocul Pharmacol Ther; 2017 Apr; 33(3):176-185. PubMed ID: 28157424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
    Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
    Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraocular pressure abnormalities associated with central and hemicentral retinal vein occlusion.
    Hayreh SS; Zimmerman MB; Beri M; Podhajsky P
    Ophthalmology; 2004 Jan; 111(1):133-41. PubMed ID: 14711725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ripasudil on diabetic macular edema.
    Minami Y; Song YS; Ishibazawa A; Omae T; Ro-Mase T; Ishiko S; Yoshida A
    Sci Rep; 2019 Mar; 9(1):3703. PubMed ID: 30842496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma.
    Komizo T; Ono T; Yagi A; Miyata K; Aihara M
    Jpn J Ophthalmol; 2019 Jan; 63(1):40-45. PubMed ID: 30368633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term safety of dexamethasone implant for treatment of macular edema due to retinal vein occlusion, in eyes with glaucoma or treated ocular hypertension.
    Theodoropoulou S; Ellabban AA; Johnston RL; Cilliers H; Mohamed Q; Sallam AB
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):725-732. PubMed ID: 27878430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of central corneal thickness on the efficacy of topical ocular hypotensive medications.
    Johnson TV; Toris CB; Fan S; Camras CB
    J Glaucoma; 2008 Mar; 17(2):89-99. PubMed ID: 18344753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Risk of Intraocular Pressure Elevation in Pediatric Noninfectious Uveitis.
    Kothari S; Foster CS; Pistilli M; Liesegang TL; Daniel E; Sen HN; Suhler EB; Thorne JE; Jabs DA; Levy-Clarke GA; Nussenblatt RB; Rosenbaum JT; Lawrence SD; Kempen JH;
    Ophthalmology; 2015 Oct; 122(10):1987-2001. PubMed ID: 26233626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term probability of intraocular pressure elevation with the intravitreal dexamethasone implant in the real-world.
    Zarranz-Ventura J; Sala-Puigdollers A; Velazquez-Villoria D; Figueras-Roca M; Copete S; Distefano L; Boixadera A; García-Arumi J; Adan A;
    PLoS One; 2019; 14(1):e0209997. PubMed ID: 30608950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occurrence of and Risk Factors for Ocular Hypertension and Secondary Glaucoma in Juvenile Idiopathic Arthritis-associated Uveitis.
    Stroh IG; Moradi A; Burkholder BM; Hornbeak DM; Leung TG; Thorne JE
    Ocul Immunol Inflamm; 2017 Aug; 25(4):503-512. PubMed ID: 27003850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.